PRE-CLINICAL MODULE Clause Samples
PRE-CLINICAL MODULE. For conduct of the Pre-Clinical Module, the Foundation shall pay the following amounts to CombinatoRx upon occurrence of the applicable even specified below:
(i) Within 30 days of the initiation of pharmacokinetic studies of a Hit, the Foundation will pay to CombinatoRx US$100,000;
(ii) Within 30 days of the selection of the first Lead Candidate, the Foundation will pay to CombinatoRx US$370,000;
(iii) Within 30 days of the selection of the first Drug Candidate, the Foundation will pay to CombinatoRx US$330,000; and
(iv) Within 30 days of filing of the first IND for a Drug Candidate or Product, the Foundation will pay to CombinatoRx US$100,000. For purposes of clarification, each of the foregoing payments shall be payable only once. In addition, except as agreed pursuant to Section 4.2, the foregoing payments reflect the full cost of doing the Research, and the Foundation will not be obligated expected to pay any additional amounts in connection with the Research.
PRE-CLINICAL MODULE. In the second module of the Research (the "PRE-CLINICAL MODULE"), CombinatoRx shall: (i) assess the pharmacokinetics of each Hit (and, as the parties deem appropriate consistent with the Research Plan, any analog, derivative or formulation thereof) in animals with the goal of identifying one or more lead candidates for further pre-clinical research (each such lead candidate being hereinafter referred to as a "LEAD CANDIDATE"); and (ii) evaluate each Lead Candidate (and, as the parties deem appropriate consistent with the Research Plan, any analog, derivative or formulation thereof) for evidence of efficacy against the Mouse Model. The parties shall mutually agree upon a strategy for progressing Hits and Lead Candidates into human clinical trails in the most expeditious manner. CombinatoRx shall disclose the results of all Pre-Clinical Module activities to the Foundation in accordance with Section 2.6, and the parties shall consult with each other with the objective of identifying at least one combination drug candidate suitable for the preparation and filing of an IND (each such combination drug candidate being hereinafter referred to as a "DRUG CANDIDATE").